Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

The SRSF4-GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy.

  • Larrasa-Alonso, Javier
  • Villalba-Orero, Maria
  • Marti-Gomez, Carlos
  • Ortiz-Sanchez, Paula
  • Lopez-Olaneta, Marina
  • Rey-Martín, M Ascensión
  • Sanchez-Cabo, Fatima
  • McNicoll, François
  • Müller-McNicoll, Michaela
  • Garcia-Pavia, Pablo
  • Lara-Pezzi, Enrique
[Figure: see text].
Repisalud
Publication Artículo científico (JournalArticle)

ATtRACT-a database of RNA-binding proteins and associated motifs

  • Giudice, Girolamo
  • Sanchez-Cabo, Fatima
  • Torroja, Carlos
  • Lara-Pezzi, Enrique
RNA-binding proteins (RBPs) play a crucial role in key cellular processes, including RNA transport, splicing, polyadenylation and stability. Understanding the interaction between RBPs and RNA is key to improve our knowledge of RNA processing, localization and regulation in a global manner. Despite advances in recent years, a unified non-redundant resource that includes information on experimentally validated motifs, RBPs and integrated tools to exploit this information is lacking. Here, we developed a database named ATtRACT (available at http://attract.cnic.es) that compiles information on 370 RBPs and 1583 RBP consensus binding motifs, 192 of which are not present in any other database. To populate ATtRACT we (i) extracted and hand-curated experimentally validated data from CISBP-RNA, SpliceAid-F, RBPDB databases, (ii) integrated and updated the unavailable ASD database and (iii) extracted information from Protein-RNA complexes present in Protein Data Bank database through computational analyses. ATtRACT provides also efficient algorithms to search a specific motif and scan one or more RNA sequences at a time. It also allows discovering de novo motifs enriched in a set of related sequences and compare them with the motifs included in the database.
Repisalud
Publication Artículo científico (JournalArticle)

Induction of the calcineurin variant CnAβ1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization

  • Lopez-Olaneta, Marina
  • Villalba-Orero, Maria
  • Gomez-Salinero, Jesus M.
  • Jimenez-Borreguero, Luis J.
  • Breckenridge, Ross
  • Ortiz-Sanchez, Paula
  • García-Pavía, Pablo
  • Ibáñez, Borja
  • Lara-Pezzi, Enrique
AIMS: Ventricular remodelling following myocardial infarction progressively leads to loss of contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the calcineurin splicing variant, CnAβ1, has beneficial effects on the infarcted heart. However, whether this variant limits necrosis or improves remodelling is still unknown, precluding translation to the clinical arena. Here, we explored the effects and therapeutic potential of CnAβ1 overexpression post-infarction. METHODS AND RESULTS: Double transgenic mice with inducible cardiomyocyte-specific overexpression of CnAβ1 underwent left coronary artery ligation followed by reperfusion. Echocardiographic analysis showed depressed cardiac function in all infarcted mice 3 days post-infarction. Induction of CnAβ1 overexpression 1 week after infarction improved function and reduced ventricular dilatation. CnAβ1-overexpressing mice showed shorter, thicker scars, and reduced infarct expansion, accompanied by reduced myocardial remodelling. CnAβ1 induced vascular endothelial growth factor (VEGF) expression in cardiomyocytes, which resulted in increased infarct vascularization. This paracrine angiogenic effect of CnAβ1 was mediated by activation of the Akt/mammalian target of rapamycin pathway and VEGF. CONCLUSIONS: Our results indicate that CnAβ1 exerts beneficial effects on the infarcted heart by promoting infarct vascularization and preventing infarct expansion. These findings emphasize the translational potential of CnAβ1 for gene-based therapies.
Repisalud
Publication Artículo científico (JournalArticle)

Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice

  • Villalba-Orero, Maria
  • Lopez-Olaneta, Marina
  • Gonzalez-Lopez, Esther
  • Padron-Barthe, Laura
  • Gomez-Salinero, Jesus M.
  • Garcia-Prieto, Jaime
  • Wai, Timothy
  • García-Pavía, Pablo
  • Ibáñez, Borja
  • Jimenez-Borreguero, Luis J.
  • Lara-Pezzi, Enrique
Aims: Heart failure (HF) has become an epidemic and constitutes a major medical, social, and economic problem worldwide. Despite advances in medical treatment, HF prognosis remains poor. The development of efficient therapies is hampered by the lack of appropriate animal models in which HF can be reliably determined, particularly in mice. The development of HF in mice is often assumed based on the presence of cardiac dysfunction, but HF itself is seldom proved. Lung ultrasound (LUS) has become a helpful tool for lung congestion assessment in patients at all stages of HF. We aimed to apply this non-invasive imaging tool to evaluate HF in mouse models of both systolic and diastolic dysfunction. Methods and results: We used LUS to study HF in a mouse model of systolic dysfunction, dilated cardiomyopathy, and in a mouse model of diastolic dysfunction, diabetic cardiomyopathy. LUS proved to be a reliable and reproducible tool to detect pulmonary congestion in mice. The combination of LUS and echocardiography allowed discriminating those mice that develop HF from those that do not, even in the presence of evident cardiac dysfunction. The study showed that LUS can be used to identify the onset of HF decompensation and to evaluate the efficacy of therapies for this syndrome. Conclusions: This novel approach in mouse models of cardiac disease enables for the first time to adequately diagnose HF non-invasively in mice with preserved or reduced ejection fraction, and will pave the way to a better understanding of HF and to the development of new therapeutic approaches.
Repisalud
Publication Capítulo o parte de un libro (BookPart)

Bayesian Inference of Gene Expression

  • Jimenez-Jimenez, Victor
  • Marti-Gomez, Carlos
  • del Pozo, Miguel Angel
  • Lara-Pezzi, Enrique
  • Sanchez-Cabo, Fatima
Omics techniques have changed the way we depict the molecular features of a cell. The integrative and quantitative analysis of omics data raises unprecedented expectations for understanding biological systems on a global scale. However, its inherently noisy nature, together with limited knowledge of potential sources of variation impacting health and disease, require the use of proper mathematical and computational methods for its analysis and integration. Bayesian inference of probabilistic models allows propagation of the uncertainty from the experimental data to our beliefs of the model parameters, allowing us to appropriately answer complex biological questions. In this chapter, we build probabilistic models of gene expression from RNA-seq data and make inference about their parameters using Bayesian methods. We present models of increasing complexity, from the quantification of a single gene expression to differential gene expression for a whole transcriptome, comparing them to the available tools for analysis of gene expression data. We provide Stan scripts that introduce the reader into the implementation of Bayesian statistics for omics data. The rationale that we apply for transcriptomics data may be easily extended to model the particularities of other omics data and to integrate the different regulatory layers.
Repisalud
Publication Artículo científico (JournalArticle)

Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes

  • Panse, Kalyani D
  • Felkin, Leanne E
  • Lopez-Olaneta, Marina
  • Gomez-Salinero, Jesus M.
  • Villalba-Orero, Maria
  • Munoz, Lucia
  • Nakamura, Kazuto
  • Shimano, Masayuki
  • Walsh, Kenneth
  • Barton, Paul J R
  • Rosenthal, Nadia
  • Lara-Pezzi, Enrique
Follistatins are extracellular inhibitors of the TGF-β family ligands including activin A, myostatin and bone morphogenetic proteins. Follistatin-like 3 (FSTL3) is a potent inhibitor of activin signalling and antagonises the cardioprotective role of activin A in the heart. FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. Here, we show that the production of FSTL3 by cardiomyocytes contributes to the paracrine activation of cardiac fibroblasts, inducing changes in cell adhesion, promoting proliferation and increasing collagen production. We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis. However, full activation requires additional factors, and we identify connective tissue growth factor as a FSTL3 binding partner in this process. Together, our data unveil a novel mechanism of paracrine communication between cardiomyocytes and fibroblasts that may provide potential as a therapeutic target in heart remodelling.
Repisalud
Publication Artículo científico (JournalArticle)

Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β

  • Padron-Barthe, Laura
  • Villalba-Orero, Maria
  • Gomez-Salinero, Jesus M.
  • Dominguez, Fernando
  • Román, Marta
  • Larrasa-Alonso, Javier
  • Ortiz-Sanchez, Paula
  • Martinez, Fernando
  • Lopez-Olaneta, Marina
  • Bonzon-Kulichenko, Elena
  • Vazquez, Jesus
  • Marti-Gomez, Carlos
  • Santiago, Demetrio J
  • Prados, Belen
  • Giovinazzo, Giovanna
  • Gómez-Gaviro, María Victoria
  • Priori, Silvia G.
  • Garcia-Pavia, Pablo
  • Lara-Pezzi, Enrique
BACKGROUND: Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in heart failure and sudden cardiac death. The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (transmembrane protein 43). The function and localization of TMEM43 are unknown, as is the mechanism by which the p.S358L mutation causes the disease. Here, we report the characterization of the first transgenic mouse model of ARVC5. METHODS: We generated transgenic mice overexpressing TMEM43 in either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal cardiomyocytes under the control of the α-myosin heavy chain promoter. RESULTS: We found that mice expressing TMEM43-S358L recapitulate the human disease and die at a young age. Mutant TMEM43 causes cardiomyocyte death and severe fibrofatty replacement. We also demonstrate that TMEM43 localizes at the nuclear membrane and interacts with emerin and β-actin. TMEM43-S358L shows partial delocalization to the cytoplasm, reduced interaction with emerin and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). Furthermore, we show that targeting cardiac fibrosis has no beneficial effect, whereas overexpression of the calcineurin splice variant calcineurin Aβ1 results in GSK3β inhibition and improved cardiac function and survival. Similarly, treatment of TMEM43 mutant mice with a GSK3β inhibitor improves cardiac function. Finally, human induced pluripotent stem cells bearing the p.S358L mutation also showed contractile dysfunction that was partially restored after GSK3β inhibition. CONCLUSIONS: Our data provide evidence that TMEM43-S358L leads to sustained cardiomyocyte death and fibrofatty replacement. Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical GSK3β inhibition improves cardiac function and increases mice life span. Our results pave the way toward new therapeutic approaches for ARVC5.
Repisalud
Publication Artículo científico (JournalArticle)

FineSplice, enhanced splice junction detection and quantification: a novel pipeline based on the assessment of diverse RNA-Seq alignment solutions

  • Gatto, Alberto
  • Torroja, Carlos
  • Mazzarotto, Francesco
  • Cook, Stuart A
  • Barton, Paul J R
  • Sanchez-Cabo, Fatima
  • Lara-Pezzi, Enrique
Alternative splicing is the main mechanism governing protein diversity. The recent developments in RNA-Seq technology have enabled the study of the global impact and regulation of this biological process. However, the lack of standardized protocols constitutes a major bottleneck in the analysis of alternative splicing. This is particularly important for the identification of exon-exon junctions, which is a critical step in any analysis workflow. Here we performed a systematic benchmarking of alignment tools to dissect the impact of design and method on the mapping, detection and quantification of splice junctions from multi-exon reads. Accordingly, we devised a novel pipeline based on TopHat2 combined with a splice junction detection algorithm, which we have named FineSplice. FineSplice allows effective elimination of spurious junction hits arising from artefactual alignments, achieving up to 99% precision in both real and simulated data sets and yielding superior F1 scores under most tested conditions. The proposed strategy conjugates an efficient mapping solution with a semi-supervised anomaly detection scheme to filter out false positives and allows reliable estimation of expressed junctions from the alignment output. Ultimately this provides more accurate information to identify meaningful splicing patterns. FineSplice is freely available at https://sourceforge.net/p/finesplice/.
Repisalud
Publication Artículo científico (JournalArticle)

Neurogenesis: Regulation by Alternative Splicing and Related Posttranscriptional Processes

  • Lara-Pezzi, Enrique
  • Desco, Manuel
  • Gatto, Alberto
  • Gómez-Gaviro, María Victoria
The complexity of the mammalian brain requires highly specialized protein function and diversity. As neurons differentiate and the neuronal circuitry is established, several mRNAs undergo alternative splicing and other posttranscriptional changes that expand the variety of protein isoforms produced. Recent advances are beginning to shed light on the molecular mechanisms that regulate isoform switching during neurogenesis and the role played by specific RNA binding proteins in this process. Neurogenesis and neuronal wiring were recently shown to also be regulated by RNA degradation through nonsense-mediated decay. An additional layer of regulatory complexity in these biological processes is the interplay between alternative splicing and long noncoding RNAs. Dysregulation of posttranscriptional regulation results in defective neuronal differentiation and/or synaptic connections that lead to neurodevelopmental and psychiatric disorders.
Repisalud
Publication Tesis doctoral (DoctoralThesis)

Retrospective clonal analysis of the developing mouse heart

  • Lioux, Ghislaine
The cardiac OFT is composed of endothelial cells (ECs), smooth muscle cells (SMCs), fibroblasts (Fbs) and Cardiomyocytes (CMs) known to derive from neural crest and second heart field (SHF) progenitors. The OFT is also covered by a mesothelial sheet of arterial mesothelial cells (AMCs) continuous with the epicardium. While the epicardium arises from the proepicardium, the early progenitor of AMCs is unknown. Using mesothelial and SHF related Cre lines we identified the origin of AMCs to be in the dorsal pharyngeal mesoderm. During a systematic analysis of cardiac lineages by random clonal labelling in developing mouse hearts, we found that AMCs shared a clonal relationship with cells of the great arteries. AMC clones were of different nature along the great arteries. On one hand, distal AMCs in both vessels were clonally related to Fbs, SMCs and ECs. On the other hand, the proximal AMCs of the Pulmonary artery (PA), were clonally related to Fbs, SMCs, CMs and lymphatic endothelial cells (LECs) of the ventral part of the heart. These clones however, were never found together with lymphatic clones of the dorsal part of the heart suggesting multiple origins for cardiac lymphatic vessels. Fate mapping of VEGFR3+ progenitors at different stages showed that whereas dorsal lymphatics derive from pre-existing lymphatic vessels, formation of ventral lymphatics involves the late recruitment of nonlymphatic cells. Using a range of SHF-specific Cre lines, we found that SHF-derived cells form ventral but not dorsal cardiac lymphatics. These observations suggest that SHF progenitors are recruited in the mesothelial-sub-mesothelial region of the PA. To test this hypothesis, we transplanted portions of PA mesothelial/sub-mesothelial layers from fluorescent donors into wild type E14.5 hearts. Donor tissue invaded the host myocardium, forming lymphatic vessels. The exploration of molecular cues involved in the formation of that niche showed that Raldh2 is downregulated at transcriptional and protein levels in proximal AMCs. Moreover, the loss of RA signalling in mesothelial cells resulted in immature lymphatic vessels while an excess of RA triggered lymphatic hyper-remodelling in the PA. These data show that part of the ventral lymphatics form by recruitment of SHF progenitors at a vasculogenic niche specified in a low Raldh2 environment at the base of the PA.
Repisalud
Publication Tesis doctoral (DoctoralThesis)

Study of Midkine-a and Caveolin-1 in zebrafish heart regeneration

  • Grivas, Dimitrios
Zebrafish have the ability to regenerate cardiac tissue after injury in contrast to mammals. Cryoinjury of the heart triggers a regenerative program that includes inflammatory response, cell proliferation and formation of a transient scar that eventually lead to complete tissue regeneration. This thesis focused on understanding the molecular and mechanical properties governing zebrafish heart regeneration. In particular, we studied the role of midkine-a (mdka) and caveolin-1 (cav1), two genes that were upregulated in a microarray analysis of regenerating hearts performed in the laboratory. Additionally, we studied the epigenetic regulation of mdka and tested in vivo different mdka cis-regulatory elements with the goal to identify the minimum regulatory regions that drive mdka expression in development and after injury. Midkine-a (Mdka) is a neurite-growth factor that is involved in the formation of the media floor plate in zebrafish. Here, we show that mdka expression was strongly induced after heart injury, although it was not expressed in intact hearts. In injured hearts, the onset of mdka expression was one-day post cryoinjury (dpci) in all the epicardial layer, whereas by 7dpci the expression became restricted to the epicardial cells covering the injured area. To study the role of Mdka in heart regeneration, we generated mdka-knock out (KO) zebrafish strains. In injured heart, mdka depletion did not trigger upregulation of mdkb and ptn, the two other members of the midkine gene family, which might compensate for the loss of Mdka. Analysis of 90dpci hearts showed that mdka deletion resulted in impaired heart regeneration, with the injured area enriched in collagen deposition. However, the proliferation ratio of cardiomyocytes (CM) and epicardial cells was not affected. Analysis of extracellular matrix turnover, immune cells infiltration in the injured area and revascularization of the regenerating tissue will clarify the reasons for the impaired cardiac regeneration in mdka-KO hearts. During development, mdka is expressed in neural tissues such us neural tube and brain, and is not detected neither in developing hearts nor in adult intact hearts. However, mdka expression was activated upon heart injury, having dynamic expression pattern. To investigate such a change in the expression pattern, we used available ChIP-seq and ATAC-seq data to analyse the epigenetic landscape of mdka. In mdka locus, there are three intronic enhancer sequences and two additional enhancers located upstream of mdka. We tested these enhancers and the mdka promoter linked to GFP reporter and studied their expression patterns in our transgenic lines. We found that the promoter of mdka and the intronic enhancers were responsible for the spatio-temporal expression pattern of mdka during development, in adult tissues and after injury of the heart and the fin. Caveolin-1 (Cav1) is the structural protein of caveolae, small membrane invaginations that are involved in signal transduction and mechanoprotection. Our expression analysis showed that Cav1 was expressed in the endocardium, endothelium and epicardium of intact adult heart. After heart cryoinjury, Cav1 was strongly expressed in epicardial cells covering the injury, and in the endocardium invading the damaged tissue. We introduced mutations in cav1 sequence that resulted in loss of Cav1 and caveolae. Analysis of the regeneration process revealed that the caveolae-depleted hearts regenerated normally, although cav1-KO hearts showed a transient defect on CM proliferation. However, loss of Cav1 and caveolae affected heart function, since the ejection fraction and the heart rate were significantly decreased in intact hearts. Using atomic force microscopy, we found that epicardial cells and cortical cardiomyocytes lacking caveolae were stiffer than the control hearts explaining the decline of cardiac function.
Repisalud
Publication Artículo científico (JournalArticle)

Activation of Serine One-Carbon Metabolism by Calcineurin A beta 1 Reduces Myocardial Hypertrophy and Improves Ventricular Function

  • Padron-Barthe, Laura
  • Villalba-Orero, Maria
  • Gomez-Salinero, Jesus M.
  • Acin-Perez, Rebeca
  • Cogliati, Sara
  • Lopez-Olaneta, Marina
  • Ortiz-Sanchez, Paula
  • Bonzon-Kulichenko, Elena
  • Vazquez, Jesus
  • Garcia-Pavia, Pablo
  • Rosenthal, Nadia
  • Enriquez, Jose Antonio
  • Lara-Pezzi, Enrique
BACKGROUND In response to pressure overload, the heart develops ventricular hypertrophy that progressively decompensates and leads to heart failure. This pathological hypertrophy is mediated, among others, by the phosphatase calcineurin and is characterized by metabolic changes that impair energy production by mitochondria. OBJECTIVES The authors aimed to determine the role of the calcineurin splicing variant CnA beta 1 in the context of cardiac hypertrophy and its mechanism of action. METHODS Transgenic mice overexpressing CnAb1 specifically in cardiomyocytes and mice lacking the unique C-terminal domain in CnA beta 1 (CnA beta 1(Delta i12) mice) were used. Pressure overload hypertrophy was induced by transaortic constriction. Cardiac function was measured by echocardiography. Mice were characterized using various molecular analyses. RESULTS In contrast to other calcineurin isoforms, the authors show here that cardiac-specific overexpression of CnA beta 1 in transgenic mice reduces cardiac hypertrophy and improves cardiac function. This effect is mediated by activation of serine and one-carbon metabolism, and the production of antioxidant mediators that prevent mitochondrial protein oxidation and preserve ATP production. The induction of enzymes involved in this metabolic pathway by CnAb1 is dependent on mTOR activity. Inhibition of serine and one-carbon metabolism blocks the beneficial effects of CnA beta 1. CnA beta 1(Delta i12) mice show increased cardiac hypertrophy and declined contractility. CONCLUSIONS The metabolic reprogramming induced by CnAb1 redefines the role of calcineurin in the heart and shows for the first time that activation of the serine and one-carbon pathway has beneficial effects on cardiac hypertrophy and function, paving the way for new therapeutic approaches. (J Am Coll Cardiol 2018; 71: 654-67) (C) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
Repisalud
Publication Artículo científico (JournalArticle)

Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

  • Domínguez, Fernando
  • Zorio, Esther
  • Jimenez-Jaimez, Juan
  • Salguero-Bodes, Rafael
  • Zwart, Robert
  • Gonzalez-Lopez, Esther
  • Molina, Pilar
  • Bermúdez-Jiménez, Francisco
  • Delgado, Juan F
  • Braza-Boïls, Aitana
  • Bornstein, Belen
  • Toquero, Jorge
  • Segovia, Javier
  • Van Tintelen, J Peter
  • Lara-Pezzi, Enrique
  • García-Pavía, Pablo
Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the most aggressive heterozygous form of ARVC. It is predominantly caused by a fully penetrant mutation (p.S358L) in the nondesmosomal gene TMEM43-endemic to Newfoundland, Canada. To date, all familial cases reported worldwide share a common ancestral haplotype. It is unknown whether the p.S358L mutation by itself causes ARVC-5 or whether the disease is influenced by genetic or environmental factors. The purpose of this study was to examine the phenotype, clinical course, and the impact of exercise on patients with p.S358L ARVC-5 without the Newfoundland genetic background. We studied 62 affected individuals and 73 noncarriers from 3 TMEM43-p.S358L Spanish families. The impact of physical activity on the phenotype was also evaluated. Haplotype analysis revealed that the 3 Spanish families were unrelated to patients with ARVC-5 with the Newfoundland genetic background. Two families shared 10 microsatellite markers in a 4.9 cM region surrounding TMEM43; the third family had a distinct haplotype. The affected individuals showed a 38.7% incidence of sudden cardiac death, which was higher in men. Left ventricular involvement was common, with 40% of mutation carriers showing a left ventricular ejection fraction of <50%. Compared with noncarriers, the R-wave voltage in lead V3 was lower (3.2 ± 2.8 mV vs 7.5 ± 3.6 mV; P < .001) and QRS complex in right precordial leads wider (104.7 ± 24.0 ms vs 88.2 ± 7.7 ms; P = .001). A history of vigorous exercise showed a trend toward more ventricular arrhythmias only in women (P = .053). ARVC-5 is associated with a high risk of sudden cardiac death and characteristic clinical and electrocardiographic features irrespective of geographical origin and genetic background. Our data suggest that, as in desmosomal ARVC, vigorous physical activity could aggravate the phenotype of TMEM43 mutation carriers.
Repisalud
Publication Artículo científico (JournalArticle)

Understanding cardiovascular disease: a journey through the genome (and what we found there)

  • Lara-Pezzi, Enrique
  • Dopazo, Ana
  • Manzanares, Miguel
Cardiovascular disease (CVD) is a major cause of mortality and hospitalization worldwide. Several risk factors have been identified that are strongly associated with the development of CVD. However, these explain only a fraction of cases, and the focus of research into the causes underlying the unexplained risk has shifted first to genetics and more recently to genomics. A genetic contribution to CVD has long been recognized; however, with the exception of certain conditions that show Mendelian inheritance, it has proved more challenging than anticipated to identify the precise genomic components responsible for the development of CVD. Genome-wide association studies (GWAS) have provided information about specific genetic variations associated with disease, but these are only now beginning to reveal the underlying molecular mechanisms. To fully understand the biological implications of these associations, we need to relate them to the exquisite, multilayered regulation of protein expression, which includes chromatin remodeling, regulatory elements, microRNAs and alternative splicing. Understanding how the information contained in the DNA relates to the operation of these regulatory layers will allow us not only to better predict the development of CVD but also to develop more effective therapies.
Repisalud
Publication Artículo científico (JournalArticle)

Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction

  • González-Santamaría, José
  • Villalba, María
  • Busnadiego, Oscar
  • Lopez-Olaneta, Marina
  • Sandoval, Pilar
  • Snabel, Jessica
  • López-Cabrera, Manuel
  • Erler, Janine T
  • Hanemaaijer, Roeland
  • Lara-Pezzi, Enrique
  • Rodríguez-Pascual, Fernando
AIMS: After myocardial infarction (MI), extensive remodelling of the extracellular matrix contributes to scar formation. While aiming to preserve tissue integrity, this fibrotic response is also associated with adverse events, including a markedly increased risk of heart failure, ventricular arrhythmias, and sudden cardiac death. Cardiac fibrosis is characterized by extensive deposition of collagen and also by increased stiffness as a consequence of enhanced collagen cross-linking. Members of the lysyl oxidase (LOX) family of enzymes are responsible for the formation of collagen cross-links. This study investigates the contribution of LOX family members to the heart response to MI. METHODS AND RESULTS: Experimental MI was induced in C57BL/6 mice by permanent ligation of the left anterior descending coronary artery. The expression of LOX isoforms (LOX and LOXL1-4) was strongly increased upon MI, and this response was accompanied by a significant accumulation of mature collagen fibres in the infarcted area. LOX expression was observed in areas of extensive remodelling, partially overlapping with α-smooth muscle actin-expressing myofibroblasts. Tumour growth factor-β as well as hypoxia-activated pathways contributed to the induction of LOX expression in cardiac fibroblasts. Finally, in vivo post-infarction treatment with the broadband LOX inhibitor β-aminopropionitrile or, selectively, with a neutralizing antibody against the canonical LOX isoform attenuated collagen accumulation and maturation and also resulted in reduced ventricular dilatation and improved cardiac function. CONCLUSION: LOX family members contribute significantly to the detrimental effects of cardiac remodelling, highlighting LOX inhibition as a potential therapeutic strategy for post-infarction recovery.
Repisalud
Publication Artículo científico (JournalArticle)

Systolic Dysfunction in Infarcted Mice Does Not Necessarily Lead to Heart Failure: Need to Refine Preclinical Models

  • Villalba-Orero, Maria
  • Lopez-Olaneta, Marina
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
Heart failure (HF) is a major cause of death and hospitalization worldwide. Despite advances in reducing mortality, prognosis remains poor and prevalence has reached epidemic proportions. The limitations of available preclinical models represent a major hurdle in the development of new therapies. Myocardial infarction (MI) is a main cause of HF in humans, and mouse models of MI are often used to study HF mechanisms and experimental treatments. We investigated whether MI in mice constitutes an appropriate model of HF. Permanent ligation of the left coronary artery induced severe and persistent systolic dysfunction and ventricular dilatation. Mouse follow-up for 10 months showed no significant evidence of lung congestion or other pulmonary defects associated with HF. No difference was observed in the capacity of infarcted mice to exercise compared to control animals. These results indicate that severe cardiac dysfunction in mice is not sufficient to demonstrate the presence of HF.
Repisalud
Publication Artículo científico (JournalArticle)

The Calcineurin Variant CnAβ1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation

  • Gomez-Salinero, Jesus M.
  • Lopez-Olaneta, Marina
  • Ortiz-Sanchez, Paula
  • Larrasa-Alonso, Javier
  • Gatto, Alberto
  • Felkin, Leanne E
  • Barton, Paul J R
  • Navarro-Lerida, Inmaculada
  • del Pozo, Miguel Angel
  • García-Pavía, Pablo
  • Sundararaman, Balaji
  • Giovinazzo, Giovanna
  • Yeo, Gene W
  • Lara-Pezzi, Enrique
Embryonic stem cells (ESC) have the potential to generate all the cell lineages that form the body. However, the molecular mechanisms underlying ESC differentiation and especially the role of alternative splicing in this process remain poorly understood. Here, we show that the alternative splicing regulator MBNL1 promotes generation of the atypical calcineurin Aβ variant CnAβ1 in mouse ESCs (mESC). CnAβ1 has a unique C-terminal domain that drives its localization mainly to the Golgi apparatus by interacting with Cog8. CnAβ1 regulates the intracellular localization and activation of the mTORC2 complex. CnAβ1 knockdown results in delocalization of mTORC2 from the membrane to the cytoplasm, inactivation of the AKT/GSK3β/β-catenin signaling pathway, and defective mesoderm specification. In summary, here we unveil the structural basis for the mechanism of action of CnAβ1 and its role in the differentiation of mESCs to the mesodermal lineage.
Repisalud
Publication Artículo científico (JournalArticle)

Lafora Disease Is an Inherited Metabolic Cardiomyopathy

Repisalud
Publication Artículo científico (JournalArticle)

WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling

  • Chen, Huimei
  • Moreno-Moral, Aida
  • Pesce, Francesco
  • Devapragash, Nithya
  • Mancini, Massimiliano
  • Heng, Ee Ling
  • Rotival, Maxime
  • Srivastava, Prashant K
  • Harmston, Nathan
  • Shkura, Kirill
  • Rackham, Owen J L
  • Yu, Wei-Ping
  • Sun, Xi-Ming
  • Tee, Nicole Gui Zhen
  • Tan, Elisabeth Li Sa
  • Barton, Paul J R
  • Felkin, Leanne E
  • Lara-Pezzi, Enrique
  • Angelini, Gianni
  • Beltrami, Cristina
  • Pravenec, Michal
  • Schafer, Sebastian
  • Bottolo, Leonardo
  • Hubner, Norbert
  • Emanueli, Costanza
  • Cook, Stuart A
  • Petretto, Enrico
Cardiac fibrosis is a final common pathology in inherited and acquired heart diseases that causes cardiac electrical and pump failure. Here, we use systems genetics to identify a pro-fibrotic gene network in the diseased heart and show that this network is regulated by the E3 ubiquitin ligase WWP2, specifically by the WWP2-N terminal isoform. Importantly, the WWP2-regulated pro-fibrotic gene network is conserved across different cardiac diseases characterized by fibrosis: human and murine dilated cardiomyopathy and repaired tetralogy of Fallot. Transgenic mice lacking the N-terminal region of the WWP2 protein show improved cardiac function and reduced myocardial fibrosis in response to pressure overload or myocardial infarction. In primary cardiac fibroblasts, WWP2 positively regulates the expression of pro-fibrotic markers and extracellular matrix genes. TGFβ1 stimulation promotes nuclear translocation of the WWP2 isoforms containing the N-terminal region and their interaction with SMAD2. WWP2 mediates the TGFβ1-induced nucleocytoplasmic shuttling and transcriptional activity of SMAD2.
Repisalud
Publication Artículo científico (JournalArticle)

The alternative heart: impact of alternative splicing in heart disease

  • Lara-Pezzi, Enrique
  • Gomez-Salinero, Jesus M.
  • Gatto, Alberto
  • García-Pavía, Pablo
Alternative splicing is the main driver of protein diversity and allows the production of different proteins from each gene in the genome. Changes in exon exclusion, intron retention or the use of alternative splice sites can alter protein structure, localisation, regulation and function. In the heart, alternative splicing of sarcomeric genes, ion channels and cell signalling proteins can lead to cardiomyopathies, arrhythmias and other pathologies. Also, a number of inherited conditions and heart-related diseases develop as a result of mutations affecting splicing. Here, we review the impact that changes in alternative splicing have on individual genes and on whole biological processes associated with heart disease. We also discuss promising therapeutic tools based on the manipulation of alternative splicing.
Repisalud
Publication Artículo científico (JournalArticle)

Guidelines for translational research in heart failure

  • Lara-Pezzi, Enrique
  • Menasché, Philippe
  • Trouvin, Jean-Hugues
  • Badimón, Lina
  • Ioannidis, John P A
  • Wu, Joseph C
  • Hill, Joseph A
  • Koch, Walter J
  • De Felice, Albert F
  • de Waele, Peter
  • Steenwinckel, Valérie
  • Hajjar, Roger J
  • Zeiher, Andreas M
Heart failure (HF) remains a major cause of death and hospitalization worldwide. Despite medical advances, the prognosis of HF remains poor and new therapeutic approaches are urgently needed. The development of new therapies for HF is hindered by inappropriate or incomplete preclinical studies. In these guidelines, we present a number of recommendations to enhance similarity between HF animal models and the human condition in order to reduce the chances of failure in subsequent clinical trials. We propose different approaches to address safety as well as efficacy of new therapeutic products. We also propose that good practice rules are followed from the outset so that the chances of eventual approval by regulatory agencies increase. We hope that these guidelines will help improve the translation of results from animal models to humans and thereby contribute to more successful clinical trials and development of new therapies for HF.
Repisalud
Publication Artículo científico (JournalArticle)

Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction

  • Ortiz-Sanchez, Paula
  • Villalba-Orero, Maria
  • Lopez-Olaneta, Marina
  • Larrasa-Alonso, Javier
  • Sanchez-Cabo, Fatima
  • Marti-Gomez, Carlos
  • Camafeita, Emilio
  • Gomez-Salinero, Jesus M.
  • Ramos-Hernandez, Laura
  • Nielsen, Peter J
  • Vazquez, Jesus
  • Müller-McNicoll, Michaela
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
RATIONALE: RBPs (RNA binding proteins) play critical roles in the cell by regulating mRNA transport, splicing, editing, and stability. The RBP SRSF3 (serine/arginine-rich splicing factor 3) is essential for blastocyst formation and for proper liver development and function. However, its role in the heart has not been explored. OBJECTIVE: To investigate the role of SRSF3 in cardiac function. METHODS AND RESULTS: Cardiac SRSF3 expression was high at mid gestation and decreased during late embryonic development. Mice lacking SRSF3 in the embryonic heart showed impaired cardiomyocyte proliferation and died in utero. In the adult heart, SRSF3 expression was reduced after myocardial infarction, suggesting a possible role in cardiac homeostasis. To determine the role of this RBP in the adult heart, we used an inducible, cardiomyocyte-specific SRSF3 knockout mouse model. After SRSF3 depletion in cardiomyocytes, mice developed severe systolic dysfunction that resulted in death within 8 days. RNA-Seq analysis revealed downregulation of mRNAs encoding sarcomeric and calcium handling proteins. Cardiomyocyte-specific SRSF3 knockout mice also showed evidence of alternative splicing of mTOR (mammalian target of rapamycin) mRNA, generating a shorter protein isoform lacking catalytic activity. This was associated with decreased phosphorylation of 4E-BP1 (eIF4E-binding protein 1), a protein that binds to eIF4E (eukaryotic translation initiation factor 4E) and prevents mRNA decapping. Consequently, we found increased decapping of mRNAs encoding proteins involved in cardiac contraction. Decapping was partially reversed by mTOR activation. CONCLUSIONS: We show that cardiomyocyte-specific loss of SRSF3 expression results in decapping of critical mRNAs involved in cardiac contraction. The molecular mechanism underlying this effect likely involves the generation of a short mTOR isoform by alternative splicing, resulting in reduced 4E-BP1 phosphorylation. The identification of mRNA decapping as a mechanism of systolic heart failure may open the way to the development of urgently needed therapeutic tools.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Severe cardiac dysfunction and death caused by arrhythmogenic right ventricular cardiomyopathy type 5 are improved by Inhibition of glycogen synthase kinase-3β

  • Padrón-Barthe, Laura
  • Villalba-Orero, María
  • Gómez-Salinero, Jesús
  • Domínguez, Fernando
  • Román, Marta
  • Larrasa-Alonso, Javier
  • Ortiz-Sánchez, Paula
  • Martínez, Fernando
  • López-Olañeta, Marina
  • Bonzón-Kulichenko, Elena
  • Vázquez, Jesús
  • Martí-Gómez, Carlos
  • Santiago, Demetrio J.
  • Prados, Belén
  • Giovinazzo, Giovanna
  • Gómez-Gaviro, María Victoria
  • Priori, Silvia
  • García Pavía, Pablo
  • Lara-Pezzi, Enrique
Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in heart failure and sudden cardiac death. The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (transmembrane protein 43). The function and localization of TMEM43 are unknown, as is the mechanism by which the p.S358L mutation causes the disease. Here, we report the characterization of the first transgenic mouse model of ARVC5. Methods: We generated transgenic mice overexpressing TMEM43 in either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal cardiomyocytes under the control of the α-myosin heavy chain promoter. Results: We found that mice expressing TMEM43-S358L recapitulate the human disease and die at a young age. Mutant TMEM43 causes cardiomyocyte death and severe fibrofatty replacement. We also demonstrate that TMEM43 localizes at the nuclear membrane and interacts with emerin and β-actin. TMEM43-S358L shows partial delocalization to the cytoplasm, reduced interaction with emerin and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). Furthermore, we show that targeting cardiac fibrosis has no beneficial effect, whereas overexpression of the calcineurin splice variant calcineurin Aβ1 results in GSK3β inhibition and improved cardiac function and survival. Similarly, treatment of TMEM43 mutant mice with a GSK3β inhibitor improves cardiac function. Finally, human induced pluripotent stem cells bearing the p.S358L mutation also showed contractile dysfunction that was partially restored after GSK3β inhibition. Conclusions: Our data provide evidence that TMEM43-S358L leads to sustained cardiomyocyte death and fibrofatty replacement. Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical GSK3β inhibition improves cardiac function and increases mice life span. Our results pave the way toward new therapeutic approaches for ARVC5, his work was supported by grants from the European Union (CardioNeT-ITN-289600 and CardioNext-608027 to Dr Lara-Pezzi), the Spanish Ministry of Economy and Competitiveness (RTI2018-096961-B-I00, SAF2015-65722-R, and SAF2012-31451 to Dr Lara-Pezzi; SAF2015-71863-REDT to Dr Garcia-Pavia), the Spanish Carlos III Institute of Health (PI14/0967 to Dr Garcia-Pavia, CPII14/00027 to Dr Lara-Pezzi; RD012/0042/0066 to Drs Garcia-Pavia and Lara-Pezzi), the Regional Government of Madrid (2010-BMD-2321 “Fibroteam” to Dr Lara-Pezzi), the Isabel Gemio Foundation (Todos somos Raros grant to Dr Garcia-Pavia), and the Spanish Society of Cardiology (2014 Basic Research Grant to Dr Garcia-Pavia). This work was also supported by the Plan Estatal de I+D+I 2013-2016–European Regional Development Fund (FEDER) “A way of making Europe,” Spain
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Extracardiac septum transversum/proepicardial endothelial cells pattern embryonic coronary arterio-venous connections

  • Cano, Elena
  • Carmona, Rita
  • Rojas, Anabel
  • Muñoz-Chápuli, Ramón
  • Pérez-Pomares, José M.
Cano, Elena et al., Recent reports suggest that mammalian embryonic coronary endothelium (CoE) originates from the sinus venosus and ventricular endocardium. However, the contribution of extracardiac cells to CoE is thought to be minor and nonsignificant for coronary formation. Using classic (Wt1) and previously undescribed (G2-Gata4) transgenic mouse models for the study of coronary vascular development, we show that extracardiac septum transversum/proepicardium (ST/PE)-derived endothelial cells are required for the formation of ventricular coronary arterio-venous vascular connections. Our results indicate that at least 20% of embryonic coronary arterial and capillary endothelial cells derive from the ST/PE compartment. Moreover, we show that conditional deletion of the ST/PE lineage-specific Wilms' tumor suppressor gene (Wt1) in the ST/PE ofG2-Gata4 mice and in the endothelium of Tie2 mice disrupts embryonic coronary transmural patterning, leading to embryonic death. Taken together, our results demonstrate that ST/PE-derived endothelial cells contribute significantly to and are required for proper coronary vascular morphogenesis., This research was supported by Ministry of Economy and Competitiveness Grants BFU2012-35799 and ISCIII-RD12/0019-0022 (to J.M.P.-P.) and BFU2011-25304 (to R.M.-C.); European Commission Seventh Framework Program-Marie Curie-Innovative Training Network Action PITNGA-2011-289600 (to J.M.P.-P.); Junta de Andalucía CTS-7564 (to R.M.-C. and J.M.P.-P.); Instituto de Salud Carlos III-Fondos FEDER Grant PI14/00814 (to A.R.); the French Government National Research Agency through the Laboratory of Excellence SIGNALIFE program (reference ANR-11-LABX-0028-01) (K.D.W.); the Association pour la Recherche sur le Cancer Grant R13026AA-ARC-WAGNER (to K.D.W.); and Fondation de France Grant FDF-U1081-WAGNER (to K.D.W.)., Peer Reviewed